{"title":"分程并行化疗方案治疗局部晚期非小细胞肺癌癌症","authors":"Eduardo Harendza","doi":"10.31579/2640-1053/026","DOIUrl":null,"url":null,"abstract":"Methods and Materials We reviewed records of 108 patients treated with regimen of split course radiotherapy (median 60 Gy in 30 fractions) and concurrent chemotherapy for stage IIIa/IIIb NSCLC. Fisher's Exact Test and Paired Student T Test were performed to identify factors predictive of development of any pulmonary toxicity (pneumonitis or fibrosis of any grade) and severe pulmonary toxicity (grade 3 or higher pneumonitis, grade 2 or higher fibrosis).","PeriodicalId":93018,"journal":{"name":"Journal of cancer research and cellular therapeutics","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment of Locally Advanced Non-small Cell Lung Cancer with our Institutional Protocol of Split Course Concurrent Chemo Irradiation\",\"authors\":\"Eduardo Harendza\",\"doi\":\"10.31579/2640-1053/026\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Methods and Materials We reviewed records of 108 patients treated with regimen of split course radiotherapy (median 60 Gy in 30 fractions) and concurrent chemotherapy for stage IIIa/IIIb NSCLC. Fisher's Exact Test and Paired Student T Test were performed to identify factors predictive of development of any pulmonary toxicity (pneumonitis or fibrosis of any grade) and severe pulmonary toxicity (grade 3 or higher pneumonitis, grade 2 or higher fibrosis).\",\"PeriodicalId\":93018,\"journal\":{\"name\":\"Journal of cancer research and cellular therapeutics\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cancer research and cellular therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31579/2640-1053/026\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer research and cellular therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31579/2640-1053/026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Treatment of Locally Advanced Non-small Cell Lung Cancer with our Institutional Protocol of Split Course Concurrent Chemo Irradiation
Methods and Materials We reviewed records of 108 patients treated with regimen of split course radiotherapy (median 60 Gy in 30 fractions) and concurrent chemotherapy for stage IIIa/IIIb NSCLC. Fisher's Exact Test and Paired Student T Test were performed to identify factors predictive of development of any pulmonary toxicity (pneumonitis or fibrosis of any grade) and severe pulmonary toxicity (grade 3 or higher pneumonitis, grade 2 or higher fibrosis).
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
